Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ritlecitinib · Litfulo

Small molecule · Inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family · developed by Pfizer

Approved FDA, Jun 2023
PFE Developer

What is Ritlecitinib?

Ritlecitinib is a kinase inhibitor that irreversibly binds the ATP site of JAK3 and TEC family kinases, inhibiting cytokine-induced STAT phosphorylation and immune receptor signaling. It is studied in severe alopecia areata.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Litfulo
Drug type
Small molecule
Targets
Janus kinase 3 (JAK3), tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family
Mechanism
Inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family
Pathways
JAK-STAT signaling, TEC kinase family immune receptor signaling
Therapy area
Dermatology
Developer
Pfizer (PFE)
FDA status
Approved as Litfulo (June 23, 2023), NDA215830 · FDA label
UNII
2OYE00PC25

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 17, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Severe Alopecia Areata

More from Pfizer

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Ritlecitinib

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.